{
    "organizations": [],
    "uuid": "7ec042f7a01e14ff6f0244d1449a6c221e6e063e",
    "author": "Reuters Editorial",
    "url": "https://www.reuters.com/article/brief-midatech-pharma-says-approval-of-i/brief-midatech-pharma-says-approval-of-investigational-new-drug-application-from-us-fda-to-conduct-study-of-mtx110-idUSFWN1PB0BP",
    "ord_in_thread": 0,
    "title": "BRIEF-Midatech Pharma Says Approval Of Investigational New Drug Application From US FDA To Conduct Study Of MTX110",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "Jan 16 (Reuters) - Midatech Pharma Plc:\n* APPROVAL OF INVESTIGATIONAL NEW DRUG APPLICATION FROM US FDA TO CONDUCT A STUDY OF MTX110\n* MTX110 IS AN INVESTIGATIONAL NANO-INCLUSION PRODUCT, FOR TREATMENT OF FATAL CHILDHOOD BRAIN CANCER DIPG Source text for Eikon: Further company coverage: (Bangalore.newsroom@thomsonreuters.com)\n ",
    "published": "2018-01-16T15:32:00.000+02:00",
    "crawled": "2018-01-17T20:10:45.005+02:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "jan",
        "reuters",
        "midatech",
        "pharma",
        "plc",
        "approval",
        "investigational",
        "new",
        "drug",
        "application",
        "u",
        "fda",
        "conduct",
        "study",
        "mtx110",
        "mtx110",
        "investigational",
        "product",
        "treatment",
        "fatal",
        "childhood",
        "brain",
        "cancer",
        "dipg",
        "source",
        "text",
        "eikon",
        "company",
        "coverage"
    ]
}